157 related articles for article (PubMed ID: 32747423)
1. Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.
Gary JM; Simmons JK; Xu J; Zhang S; Peat TJ; Watson N; Gamache BJ; Zhang K; Kovalchuk AL; Michalowski AM; Chen JQ; Thaiwong T; Kiupel M; Gaikwad S; Etienne M; Simpson RM; Dubois W; Testa JR; Mock BA
Mol Cancer Ther; 2020 Oct; 19(10):2221-2232. PubMed ID: 32747423
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Chilosi M; Doglioni C; Yan Z; Lestani M; Menestrina F; Sorio C; Benedetti A; Vinante F; Pizzolo G; Inghirami G
Am J Pathol; 1998 Jan; 152(1):209-17. PubMed ID: 9422538
[TBL] [Abstract][Full Text] [Related]
3. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
[TBL] [Abstract][Full Text] [Related]
4. Ovatodiolide, isolated from Anisomeles indica, suppresses bladder carcinogenesis through suppression of mTOR/β-catenin/CDK6 and exosomal miR-21 derived from M2 tumor-associated macrophages.
Wu ATH; Srivastava P; Yadav VK; Tzeng DTW; Iamsaard S; Su EC; Hsiao M; Liu MC
Toxicol Appl Pharmacol; 2020 Aug; 401():115109. PubMed ID: 32544403
[TBL] [Abstract][Full Text] [Related]
5. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas.
Snijders AM; Liu Y; Su L; Huang Y; Mao JH
Oncotarget; 2015 Dec; 6(42):44794-805. PubMed ID: 26575021
[TBL] [Abstract][Full Text] [Related]
7. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
[TBL] [Abstract][Full Text] [Related]
8. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.
Ling Z; Fang ZG; Wu JY; Liu JJ
Kaohsiung J Med Sci; 2021 May; 37(5):392-401. PubMed ID: 33615686
[TBL] [Abstract][Full Text] [Related]
9. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
13. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
14. KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.
Pekkonen P; Järviluoma A; Zinovkina N; Cvrljevic A; Prakash S; Westermarck J; Evan GI; Cesarman E; Verschuren EW; Ojala PM
Cell Cycle; 2014; 13(23):3670-84. PubMed ID: 25483078
[TBL] [Abstract][Full Text] [Related]
15. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
16. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
17. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
[TBL] [Abstract][Full Text] [Related]
18. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
19. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
20. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]